Additional file 5 of RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma
FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistan
Gemcitabine (GEM) alone and GEM-based chemotherapy are the preferred regimens for treating advanced unresectable and metastatic pancreatic cancer (PC). However, these treatments have limited efficacy
PurposeThe tripartite motif-containing family member TRIM37 is involved in a number of important biological and pathological processes, and it has recently been shown to be an essential regulator of p
The goal of this study was to determine the transcriptional changes in pancreatic cancer cells after treatment with gemcitabine. Overall design: HPAFII cells were treated with PBS or Gemcitabine for 7
We performed RNA-seq to investigate gene expression changes in pancreatic cancer cells following chemotherapeutic drug treatment. We identify a reversible senescence state among the drug-tolerant pers